Status:
RECRUITING
QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry
Lead Sponsor:
SeaStar Medical
Conditions:
Acute Kidney Injury
Acute Kidney Injury Due to Sepsis
Eligibility:
All Genders
Up to 22 years
Brief Summary
QUELIMMUNE is FDA-approved under an HDE for the treatment of pediatric patients (weight ≥10kg and age ≤22 years) with AKI due to sepsis or a septic condition on antibiotic therapy and requiring RRT. ...
Eligibility Criteria
Inclusion
- All patients initiated on QUELIMMUNE therapy under the HDE-approved indication
Exclusion
- Weight \<10kg
- Age \>22 years
- Known allergy to any components of QUELIMMUNE
Key Trial Info
Start Date :
July 19 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06517810
Start Date
July 19 2024
End Date
May 1 2026
Last Update
October 24 2025
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's of Alabama
Birmingham, Alabama, United States, 35233
2
Lucile Packard Children's Hospital Stanford
Palo Alto, California, United States, 94304
3
UCSF Benioff Children's
San Francisco, California, United States, 94618
4
Children's Hospital of Atlanta - Arthur M. Blank
Atlanta, Georgia, United States, 30329